Lantern Pharma Inc.
No enriched coverage for $LTRN in the last 7 days.
No SEC Form 4 filings for $LTRN in the last 30 days.
See all $LTRN insider activity →Lantern Pharma Inc. seeks stockholder approval to increase authorized common shares from 25M to 50M and issue up to 3.67M shares via warrants. The proposal, part of seven items on the December 1, 2026 agenda, may dilute shares if approved. As of October 5, 2026, 14.94M shares were outstanding.
Lantern Pharma (LTRN) received approvals in Taiwan to expand Part 2 of its Phase 2 trial for LP-300 in non-smoker lung cancer, increasing dosing to eight cycles. U.S. approvals are in place, and patient identification is underway.
Lantern Pharma (LTRN) received a notice from Nasdaq on September 25, 2026, for failing to meet listing rules due to its market value of listed securities being below $35 million for 30 consecutive business days. The company has until March 24, 2027, to regain compliance by achieving a market value of at least $35 million for 10 consecutive business days. Failure to comply may result in delisting from the Nasdaq Capital Market.
Recent LTRN coverage spans financial news, corporate actions and earnings.
Potential dilution and increased equity capacity could pressure the stock if approved.
Positive regulatory milestone expands trial scope, likely supporting near‑term share price.
Potential delisting risk creates downside pressure on the stock.
The dilution from the $8 M raise is expected to put short‑term pressure on the stock.
Positive IP milestone may support future valuation and reduce competitive risk.
AlphAI scores every news story that mentions LTRN with an AI model for sentiment and relevance, and aggregates insider trades from Lantern Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lantern Pharma Inc. seeks stockholder approval to increase authorized common shares from 25M to 50M and issue up to 3.67M shares via warrants. The proposal, part of seven items on the December 1, 2026 agenda, may dilute shares if approved. As of October 5, 2026, 14.94M shares were outstanding.
1 min readLantern Pharma (LTRN) received approvals in Taiwan to expand Part 2 of its Phase 2 trial for LP-300 in non-smoker lung cancer, increasing dosing to eight cycles. U.S. approvals are in place, and patient identification is underway.
1 min readLantern Pharma (LTRN) received a notice from Nasdaq on September 25, 2026, for failing to meet listing rules due to its market value of listed securities being below $35 million for 30 consecutive business days. The company has until March 24, 2027, to regain compliance by achieving a market value of at least $35 million for 10 consecutive business days. Failure to comply may result in delisting from the Nasdaq Capital Market.
1 min readLantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering $4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of the warrants DALLAS, TEXAS — (BUSINESS WIRE) — September 29, 2026 – Lan
2 min readLantern Pharma (LTRN) received a USPTO Notice of Allowance for LP-284, extending patent protection to 2042 for treating mantle cell lymphoma and double-hit lymphoma. The patent covers LP-284 as a monotherapy and in combination with other anti-cancer agents. LP-284 is in a Phase 1 clinical trial and has three FDA Orphan Drug Designations.
2 min readLantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.
2 min readLantern Pharma (LTRN) has a cash runway of about 6 months, with $7.4M in cash and a $14M annual burn rate. While its burn rate decreased 21% year-over-year, the company's burn is high relative to its $30M market cap, raising concerns about its ability to fund operations. The company is debt-free but may need to raise cash soon.
2 min readLantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM
6 min readLantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.
3 min readNew to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).
2 min read
